Measuring the psychosocial impact of population-based prostate-specific antigen testing for prostate cancer in the UK.

Measuring the psychosocial impact of population-based prostate-specific antigen testing for prostate cancer in the UK.

OBJECTIVE: To evaluate the psychosocial impact of participation in a population-based prostate-specific antigen (PSA) testing programme, akin to screening, and to explore the relationship between urinary symptoms reported before PSA testing and the response to the subsequent PSA result. PATIENTS AN...

Bibliografske podrobnosti
Main Authors:	Brindle, L, Oliver, SE, Dedman, D, Donovan, J, Neal, D, Hamdy, F, Lane, J, Peters, T
Format:	Journal article
Jezik:	English
Izdano:	2006

Podobne knjige/članki

Population-based prostate-specific antigen testing in the UK leads to a stage migration of prostate cancer.
od: Moore, A, et al.
Izdano: (2009)

Predictors of attendance for prostate-specific antigen screening tests and prostate biopsy.
od: Avery, K, et al.
Izdano: (2012)

Predictors of attendance for prostate-specific antigen screening tests and prostate biopsy
od: Avery, K, et al.
Izdano: (2012)

Seasonal variation in prostate-specific antigen levels: A large cross-sectional study of men in the UK
od: Down, L, et al.
Izdano: (2011)

Seasonal variation in prostate-specific antigen levels: a large cross-sectional study of men in the UK.
od: Down, L, et al.
Izdano: (2011)

Prostate Testing for Cancer and Treatment (ProtecT) feasibility study
od: J. Donovan, et al.
Izdano: (2003-01-01)

Prostate cancer detection in men aged 45-49 years in the UK protect (prostate testing for cancer and treatment) trial
od: Hamdy, F, et al.
Izdano: (2006)

Prostate-specific antigen (PSA) testing of men in UK general practice: a 10-year longitudinal cohort study
od: Young, GJ, et al.
Izdano: (2017)

The protecT (prostate testing for cancer and treatment) study: Evaluating screening and treatment of clinically localised prostate cancer in the UK
od: Hamdy, F, et al.
Izdano: (2006)

Do the risk factors of age, family history of prostate cancer or a higher prostate specific antigen level raise anxiety at prostate biopsy?
od: Macefield, R, et al.
Izdano: (2009)

The value of repeat serum PSA measurements in the detection of prostate cancer - Experience from the feasibility phase of the UK protect study
od: Hamdy, F, et al.
Izdano: (2006)

Prostate-specific antigen testing and prostate biopsy: are self-reported lower urinary tract symptoms and health-related quality of life associated with the decision to undergo these investigations?
od: Avery, K, et al.
Izdano: (2008)

Serum insulin-like growth factor-I is positively associated with serum prostate-specific antigen in middle-aged men without evidence of prostate cancer.
od: Oliver, SE, et al.
Izdano: (2004)

Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: prospective evaluation within ProtecT study
od: Rosario, D, et al.
Izdano: (2012)

Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: prospective evaluation within ProtecT study.
od: Rosario, D, et al.
Izdano: (2012)

Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: Prospective evaluation within ProtecT study
od: Rosario, D, et al.
Izdano: (2012)

Prostate-specific antigen testing rates remain low in UK general practice: a cross-sectional study in six English cities.
od: Williams, N, et al.
Izdano: (2011)

Prostate-specific antigen testing rates remain low in UK general practice: A cross-sectional study in six English cities
od: Williams, N, et al.
Izdano: (2011)

The protect (prostate testing for cancer and treatment) study: Advanced cases found through a UK screening study
od: Neal, D, et al.
Izdano: (2006)

Contribution of a single repeat PSA test to prostate cancer risk assessment: experience from the ProtecT study.
od: Rosario, D, et al.
Izdano: (2008)

Longitudinal prostate-specific antigen reference ranges: Choosing the underlying model of age-related changes
od: Simpkin, A, et al.
Izdano: (2013)

ASSOCIATIONS OF SEXUAL DYSFUNCTION WITH LOCALIZED AND ADVANCED PROSTATE CANCER: A CASE-CONTROL STUDY NESTED WITHIN THE UK POPULATION-BASED PROTECT (PROSTATE TESTING FOR CANCER AND TREATMENT) STUDY
od: Collin, S, et al.
Izdano: (2009)

ASSOCIATION OF ANTHROPOMETRIC AND LIFESTYLE FACTORS WITH PROSTATE SPECIFIC ANTIGEN (PSA) TRAJECTORIES IN MEN WITH LOCALISED PROSTATE CANCER UNDERGOING ACTIVE MONITORING
od: Burton, A, et al.
Izdano: (2011)

Systematic review and meta-analysis of the associations between body mass index, prostate cancer, advanced prostate cancer, and prostate-specific antigen
od: Harrison, S, et al.
Izdano: (2020)

The relationship between prostate-specific antigen and prostate cancer risk: the Prostate Biopsy Collaborative Group.
od: Vickers, A, et al.
Izdano: (2010)

Associations of sexual dysfunction symptoms with PSA-detected localised and advanced prostate cancer: a case-control study nested within the UK population-based ProtecT (Prostate testing for cancer and Treatment) study.
od: Collin, S, et al.
Izdano: (2009)

Latest results from the UK trials evaluating prostate cancer screening and treatment: the CAP and ProtecT studies.
od: Lane, J, et al.
Izdano: (2010)

Associations of folate, vitamin B12, homocysteine, and folate-pathway polymorphisms with prostate-specific antigen velocity in men with localized prostate cancer.
od: Collin, S, et al.
Izdano: (2010)

Association of diabetes mellitus with prostate cancer: nested case-control study (Prostate testing for cancer and treatment study).
od: Turner, E, et al.
Izdano: (2011)

Development of a new method for monitoring prostate-specific antigen changes in men with localised prostate cancer: a comparison of observational cohorts.
od: Tilling, K, et al.
Izdano: (2010)

Measurement of insulin-like growth factor axis does not enhance specificity of PSA-based prostate cancer screening.
od: Oliver, SE, et al.
Izdano: (2004)

Investigating the prostate specific antigen, body mass index and age relationship: is an age-BMI-adjusted PSA model clinically useful?
od: Harrison, S, et al.
Izdano: (2016)

Detection of prostate cancer in unselected young men: prospective cohort nested within a randomised controlled trial.
od: Lane, J, et al.
Izdano: (2007)

Measurement of the insulin-like growth factor (IGF)-axis does not enhance the specificity of PSA-based prostate cancer screening.
od: Oliver, SE, et al.
Izdano: (2002)

Screening for prostate cancer. The case against.
od: Donovan, J, et al.
Izdano: (2005)

Experiences and decision processes during PSA testing and prostate biopsy: A qualitative study
od: Avery, K, et al.
Izdano: (2007)

Who can best recruit to randomized trials? Randomized trial comparing surgeons and nurses recruiting patients to a trial of treatments for localized prostate cancer (the ProtecT study).
od: Donovan, J, et al.
Izdano: (2003)

10-year outcomes in localized prostate cancer.
od: Hamdy, F, et al.
Izdano: (2017)

THE PROTECT TRIAL - EVALUATING THE EFFECTIVENESS OF TREATMENTS FOR CLINICALLY LOCALISED PROSTATE CANCER
od: Lane, J, et al.
Izdano: (2009)

Prostate cancer: screening approaches.
od: Donovan, J, et al.
Izdano: (2005)